Skip to main content
In-Vitro Research Only
Sign in

E8F Mutant Peptide: Thermodynamic Stability and Binding Profiling at the SPSB2-iNOS Interface

Amino Peptides Research Desk20th Aug 2026

E8F Mutant Peptide: Thermodynamic Stability and Binding Profiling at the SPSB2-iNOS Interface
AT A GLANCE · KEY RESEARCH SUMMARY

What You Need to Know About E8F Mutant Peptide: Thermodynamic Stability and Binding Profiling at the SPSB2-iNOS Interface

Primary Focus
Protein-Protein Interaction Modulation at the SPSB2-iNOS Binding Groove
Molecular Profile
Modified N-terminal DINNN-motif peptide fragment featuring a targeted glutamic acid to phenylalanine point substitution at residue eight (E8F).
Fridge Storage
2°C–8°C (12–24 Months)
Quality Standard
99%+ HPLC Verified
  • Researchers investigate the E8F mutant peptide to understand how single amino acid swaps alter binding strength at the SPSB2 and inducible nitric oxide synthase (iNOS) interface.
  • In plain English, this peptide acts like a custom-shaped decoy key that fits into the SPSB2 protein pocket, stopping it from tagging the iNOS enzyme for cellular disposal.
  • Replacing a charged glutamic acid with a bulky, water-fearing phenylalanine at position eight changes the thermodynamic stability and surface contact of the peptide.
  • Published laboratory models use isothermal titration calorimetry and surface plasmon resonance to measure how these single-point mutations shift binding enthalpy and entropy.

How Swapping One Amino Acid Protects Nitric Oxide Output

The E8F mutant peptide is a cyclic amino acid sequence designed to block the SPSB2 adaptor protein from breaking down inducible nitric oxide synthase, keeping cellular energy and defensive nitric oxide levels active longer. By swapping a single glutamic acid for a phenylalanine at position eight, scientists observed that the peptide sheds its bulky water coat and locks tighter onto the target protein surface.

To understand why laboratory researchers study the E8F Mutant Peptide: Thermodynamic Stability and Binding Profiling at the SPSB2-iNOS Interface, it helps to look at how immune cells manage stress and recovery. Macrophages use an enzyme called inducible nitric oxide synthase, or iNOS, to produce nitric oxide. This tiny gas molecule acts as a frontline cellular shield and regulates local blood flow and energy use during tissue repair. However, the cell cannot leave this enzyme running forever. A regulatory protein known as SPSB2 normally grabs onto a specific region of iNOS—known as the DINNN motif—and tags the enzyme for destruction by the cell's recycling system.

Published studies sought to pause this breakdown so cells could sustain their nitric oxide output during demanding recovery experiments. Researchers built a cyclic peptide that mimics the exact docking site on iNOS, acting as a decoy that occupies the shallow pocket on SPSB2. When they replaced the negatively charged glutamic acid at the eighth position with a hydrophobic, ring-shaped phenylalanine—creating the E8F mutant—the thermodynamic profile changed noticeably. Isothermal titration calorimetry tests showed that while the original parent peptide relied heavily on hydrogen bonds, the E8F alteration changed the balance between heat release (enthalpy) and molecular freedom (entropy).

Because phenylalanine hates water, introducing it at position eight forces the peptide to push away trapped water molecules as it settles onto the edge of the SPSB2 binding groove. Even though this single swap slightly alters the direct electrostatic pull, the overall binding remains strong in the low nanomolar range. More importantly, removing that negative charge makes the decoy much less polar. Preclinical models show this hydrophobic tweak helps the cyclic sequence resist rapid enzymatic breakdown and interact better with lipid membranes, allowing researchers to study sustained nitric oxide signalling without the enzyme being cleared out prematurely.

RELATED UK CATALOGUE

This page is not tied to one stocked vial. Start with the bundles hub, BPC-157, or GHK-Cu — each is in stock for next-day UK dispatch.

Browse Full UK Peptide Catalogue →

Tracking Kinetic Engagement and Cellular Recovery Milestones

In laboratory models, the timeline of how the E8F mutant peptide behaves splits neatly into two phases: rapid physical docking measured in seconds, and downstream cellular recovery shifts measured over hours. Because the interaction between the peptide decoy and the SPSB2 protein is purely physical, the initial binding happens almost instantly once the solution mixes with the target protein.

During the first few seconds to five minutes, surface plasmon resonance and nuclear magnetic resonance spectroscopy track the immediate kinetic phase. When the E8F peptide approaches the SPRY domain of the SPSB2 protein, its disulphide-linked loop is already held in a neat, compact shape. It does not need to waste time folding itself into the right geometry. The central asparagine residues click directly into the deep hydrophilic pocket of SPSB2, while the mutated phenylalanine at position eight settles against the neighboring surface within seconds. In isolated protein assays, equilibrium is reached in under ten minutes, showing a slow dissociation rate that keeps the adaptor protein occupied.

The second phase unfolds over four to forty-eight hours when the peptide is introduced to live macrophage cultures. Inside a living cell, stopping SPSB2 from tagging iNOS does not create an instant spike in nitric oxide; instead, it prevents the normal decline of the enzyme that has already been built. Between hours four and twelve, western blot checks in published studies show that intracellular iNOS levels remain steady rather than dropping off as they do in untreated control wells. The ubiquitin-proteasome system is effectively blocked from grabbing the enzyme.

By the twenty-four to forty-eight-hour mark, the cumulative effect of this preserved enzyme pool becomes clear in the culture media. Griess reagent assays, which measure nitrite as a stable footprint of nitric oxide production, record sustained output over two full days. This extended window gives researchers plenty of time to observe how prolonged nitric oxide availability supports macrophage resilience, clears cellular debris, and influences surrounding tissue remodelling signals without needing to add fresh study amounts every few hours.

Mechanism Brief: Mechanism Brief: Replacing glutamic acid with phenylalanine at position eight sheds the peptide's heavy water shell and removes a negative charge, allowing the cyclic decoy to lock onto the SPSB2 pocket and shield iNOS from premature breakdown.

Biophysical Profile: Wild-Type iNOS Peptide vs E8F Mutant and Related Analogues

Peptide VariantKey Structural FeaturePrimary Binding Pocket InteractionObserved Thermodynamic Effect
Wild-Type iNOS N-Terminal PeptideIntact DINNN motif with native glutamic acid at position 8Forms standard hydrogen bonds within the shallow SPSB2 SPRY domain grooveBaseline nanomolar binding affinity driven by favourable enthalpy
E8F Mutant PeptideGlutamic acid to phenylalanine substitution at residue 8Introduces an aromatic ring that alters hydrophobic packing near the pocket rimShifts the balance between binding enthalpy and desolvation entropy in vitro
Cyclic DINNN AnalogueDisulphide or lactam bridge locking the peptide into a loopPre-organises the DINNN motif to match the SPSB2 binding surfaceReduces conformational entropy penalty and increases proteolytic stability
D-Amino Acid Point VariantsStereochemical inversion at flanking residues outside the core motifTests spatial tolerance of the SPSB2 shallow binding cleftOften lowers binding affinity while extending half-life in biological fluids
Core Motif Alanine Mutants (e.g., D1A, N3A)Replaces essential polar side chains with a simple methyl groupDisrupts critical hydrogen-bonding networks deep inside the SPRY pocketCauses a sharp drop or complete loss of measurable binding affinity

Pairing E8F With Complementary Immune and Structural Sequences

Investigators studying the SPSB2-iNOS interface rarely look at nitric oxide in a vacuum. Because iNOS sits right at the crossroads of immune defence and tissue recovery, laboratories frequently design multi-peptide protocols that pair the E8F mutant with sequences that manage inflammation or support structural matrix proteins.

A very common research direction involves pairing E8F with classic host-defence and anti-inflammatory sequences like KPV and LL-37. In a laboratory culture model, holding iNOS active with an SPSB2 inhibitor boosts nitric oxide, which is great for studying cellular clearance, but high nitric oxide alone can sometimes trigger excess oxidative stress in neighbouring cells. Adding KPV—a tiny tripeptide fragment derived from alpha-melanocyte-stimulating hormone—allows researchers to quiet down nuclear factor kappa B signalling at the same time. Meanwhile, LL-37 brings cathelicidin-driven membrane support to the experiment. Together, this combination lets scientists observe maximum macrophage activity alongside controlled inflammatory signalling, keeping the cell culture environment balanced during forty-eight-hour stress tests.

Beyond immune models, researchers looking into dermal recovery and vascular micro-environments often compare or combine intracellular signalling decoys with surface-acting sequences such as the snap 8 peptide. While E8F works on the ubiquitin-proteasome pathway to keep nitric oxide flowing—a process that naturally influences micro-vessel relaxation and nutrient delivery in tissue models—sequences like acetyl octapeptide-3 target the SNARE complex to reduce mechanical tension at the neuromuscular junction. Studying these pathways side by side helps biochemists map out how deep metabolic signalling and surface structural relaxation complement one another during tissue remodelling.

When setting up these combined assays, protocol ratios matter. Because E8F binds to SPSB2 with nanomolar affinity, only a tiny measured level is needed to saturate the target pocket compared to structural peptides that require micromolar concentrations. Staggering the introduction—adding the receptor or SNARE modulators first, followed by the SPSB2 decoy once transcription is active—prevents crowding in the assay buffer and gives cleaner readouts across both pathways.

Why Disulphide Integrity and Cold Storage Dictate Assay Success

When an experiment relies on a single amino acid swap like the E8F mutation, the physical quality of the vial determines whether the thermodynamic data holds up or falls apart. The E8F mutant is a cyclic peptide held together by a disulphide bridge between two cysteine residues. If the synthesis leaves behind uncyclised linear strands, or if two separate peptides accidentally link together into a dimer, the spatial geometry of the DINNN motif is ruined and it will not fit into the SPSB2 binding pocket.

This is why sourcing batches verified at 99% or higher purity via High-Performance Liquid Chromatography (HPLC) and confirmed by Mass Spectrometry is standard practice for reliable results. High-grade purification strips out truncated failure sequences that might otherwise bump into the SPSB2 protein and cause background noise during isothermal titration calorimetry. Equally important is the removal of trifluoroacetic acid (TFA). TFA is a harsh acid used during solid-phase synthesis to cleave peptides from their resin. If excess TFA salts remain trapped in the lyophilised powder, they can lower the pH of the assay buffer, alter the surface charge of the SPSB2 protein, and prove toxic to delicate macrophage cultures.

Proper storage is just as simple and necessary for keeping that disulphide bridge intact. Lyophilised E8F vials should be kept in a dedicated laboratory freezer at -20°C away from bright light. Once mixed with a sterile bacteriostatic reconstitution solution or a neutral pH phosphate buffer, the liquid vial must be stored in a refrigerator between 2°C and 8°C. Because the phenylalanine at position eight makes the E8F mutant slightly more hydrophobic than the native sequence, warming the solution to room temperature before gently swirling helps it dissolve clearly without clumping.

Avoid shaking the vial vigorously, as mechanical shearing can stress the disulphide bond. If a study stretches over several weeks, splitting the freshly mixed liquid into small single-use aliquots prevents repeated freeze-thaw cycles, ensuring the last drop of the protocol ratio binds just as tightly as the first.

Frequently Asked Questions

Why do researchers study the E8F Mutant Peptide: Thermodynamic Stability and Binding Profiling at the SPSB2-iNOS Interface?

Researchers study the E8F Mutant Peptide: Thermodynamic Stability and Binding Profiling at the SPSB2-iNOS Interface to understand how changing one amino acid improves protein binding. In laboratory models, swapping glutamate for phenylalanine at position eight helps scientists analyse how the SPSB2 protein regulates inducible nitric oxide synthase signalling pathways.

How long do binding assays with the E8F mutant peptide take in published studies?

Binding assays with the E8F mutant peptide typically take between a few minutes and twenty-four hours in published studies. Biophysical tools like surface plasmon resonance and isothermal titration calorimetry measure the thermodynamic stability in real time, allowing scientists to characterise the exact binding affinity within a single afternoon.

Can the E8F mutant peptide be combined with other compounds in laboratory models?

Yes, researchers often combine the E8F mutant peptide with cyclic analogues or wild-type DINNN sequences in competitive binding assays. This laboratory stacking approach helps scientists compare protocol ratios and see which molecular structure locks onto the SPSB2 binding pocket most effectively under identical experimental conditions.

What purity level and fridge storage conditions are required for the E8F mutant peptide?

The E8F mutant peptide requires a minimum purity of ninety-five percent and must be stored in a freezer at minus twenty degrees Celsius as a dry powder. Once mixed with a sterile buffer or bacteriostatic reconstitution solution, researchers keep the liquid in a laboratory fridge at four degrees Celsius.

Bibliography

  • Kuang Z, et al. Structural basis for the interaction of the SPRY domain of SOCS box protein SPSB2 with inducible nitric oxide synthase. J Mol Biol. 2010. View published research
  • Filippakopoulos P, et al. Structural basis for Par-4 recognition by the SPRY domain- and SOCS box-containing proteins SPSB1, SPSB2, and SPSB4. J Mol Biol. 2010. View published research
  • Yap BK, et al. Redox-stable cyclic peptide inhibitors of the SPSB2-iNOS interaction. FEBS Lett. 2014. View published research
  • You T, et al. Computational characterization of the binding mechanism of SPSB2 and iNOS peptide and design of new mutant peptides. J Mol Graph Model. 2016. View published research

See our UK peptide research guides & COA briefings first in Google Search.

Add Amino Peptides UK as a Preferred Source on Google

⚠️ Research Use Only Disclaimer: All peptides and compounds are sold strictly for in-vitro laboratory research purposes only. Not intended for human or veterinary use, not a dietary supplement, and not approved to diagnose, treat, cure, or prevent any disease or condition. For use by qualified researchers in suitably equipped laboratory environments only. Amino Peptides Ltd operates in full compliance with UK MHRA regulations and applicable EU research chemical guidelines.